<DOC>
	<DOCNO>NCT02836873</DOCNO>
	<brief_summary>The purpose study investigate effect bexagliflozin lower hemoglobin A1c ( HbA1c ) level patient type 2 diabetes mellitus ( T2DM ) moderate renal impairment .</brief_summary>
	<brief_title>Safety Efficacy Bexagliflozin Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment</brief_title>
	<detailed_description>Approximately 52 investigative site globally plan participate study . An estimated 300 subject poorly control T2DM moderate renal impairment randomly assign receive bexagliflozin tablet , 20 mg , placebo equal ratio 24 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1 . Males females T2DM inadequate glycemic control 2 . Diagnosis moderate renal impairment 4 ) Body Mass Index â‰¤ 45 kg/m2 1 . Diagnosis type 1 diabetes mellitus maturityonset/diabetes young 2 . Women pregnant nursing 3 . Subjects receive renal replacement therapy undergone renal transplantation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>